Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc., in collaboration with Asher Biotherapeutics, Inc., is launching a Phase 1b clinical study titled A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311). The study aims to assess the safety and tolerability of combining tarlatamab with AB248, focusing on determining the optimal dosage for further trials. This research is significant as it explores potential new treatment avenues for extensive stage small cell lung cancer, a challenging condition to treat.
The study will test the combination of two drugs, Tarlatamab and AB248, both administered via intravenous infusion. Tarlatamab is a drug designed to target cancer cells, while AB248 is being tested to enhance the efficacy of Tarlatamab.
The study is designed as an interventional trial with a non-randomized, sequential intervention model. It is open-label, meaning there is no masking, and its primary purpose is treatment-focused. This design allows for a thorough exploration of dosage levels to establish the maximum tolerated dose of the drug combination.
Key dates for the study include an estimated start date of August 29, 2025, with the study first submitted on June 17, 2025. The last update was submitted on August 19, 2025. These dates are crucial as they mark the timeline for the study’s progression and data availability.
The announcement of this study could have significant implications for Amgen’s stock performance and investor sentiment. As the study progresses, positive results could enhance Amgen’s market position, especially in the competitive oncology sector. Investors will be keenly watching for updates, as successful trials could lead to new treatment options and increased market share.
The study is currently not yet recruiting, and further details are available on the ClinicalTrials portal.